Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.
Jeffrey Casberg, senior director of pharmacy at IPD Analytics, talks about some of the high-impact specialty drugs he highlighted in his session at AMCP 2023.
What high-impact specialty drugs have been approved recently, and what impacts have they made?
The drugs I'm going to talk about here for a minute or 2, some may have just been approved, or many of them are pipeline products that are the ones that I just spoke about at AMCP this week and could be of interest to payers and pharma in the future.
The first one I'll talk about is Syfovre, it's a new drug for dry AMD. In the United States, in this ophthalmic condition that can cause blindness, about 85% of the patients have dry AMD and only about 15% have wet [AMD]. In the previous 10 to 20 years, we've been able to treat the wet AMD with Eylea and products like that. But with this new Syfovre, for geographic atrophy secondary to wet AMD, it's kind of a new therapy which will prevent blindness of patients moving forward. It's kind of a landmark breakthrough in the treatment of this ophthalmic condition. It's given every 25 to 60 days. So in some ways, the doctors use their own knowledge and seeing how the patient's progressing, and then either dose them or let them go on and then dose them a few weeks later. So the docs kind of keep track of that. It's about 1 million patients in the United States with this condition, but 75% of the patients are going to end up getting the drug, we think, every 60 days rather than every 25 days or so. So that's kind of a interesting new therapeutic area.
Along with that, in the same category actually, is this dry AMD, and Eylea has been the leading product in that category for many years. But they've recently come upon some increased competition and, as well, their patent life is coming up. So Regeneron is coming up with a new Eylea HD, which instead of being dosed, I think it's dosed every 8 to 12 weeks, it's now going to be dosed with a higher milligram strength but every 16 weeks. So they're trying to come up with a product to improve dosing for the patient, but also maintain their revenue for Regeneron, and that's going to be coming up for approval in a few months.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More